Kyowa Kirin : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)

November 1, 2023

Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS)

Fiscal 2023 Third Quarter

(January 1, 2023 - September 30, 2023)

• These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on November 1, 2023 for the first nine months of Fiscal 2023, from January 1, 2023 to September 30, 2023.
• This document is an English translation of the Japanese-language original.
• The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
• Figures presented in these materials have been rounded to the nearest tenth
• Figures inside parenthesis presented in these materials indicate negative values.
• Change amount in these materials presents change amount compared to the same period of the previous fiscal year.

Index	Page

1. Consolidated Financial Results

1.	Trends in consolidated profit	1
2.	Revenue by regional control function	2
3.	Revenue by location of customer	2
4.	Capital expenditures and intangible assets investment,	2
	depreciation and amortization
5.	Number of employees by regional control function	2
II. Consolidated Statement of Cash Flows	2
Ⅲ. Revenue from Main Products	3
Ⅳ. R&D Pipeline	6

The average exchange rates for each period were as follows:

									Unit: Yen
		FY 2022 results		FY 2023 results		FY 2023
				forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
USD	114	120	126	130	132	134		137	130
GBP	154	158	160	161	161	164		170	160
EUR	129	133	135	137	141	144		148	135

Contact

Kyowa Kirin Co., Ltd.

Corporate Communications Department

Tel [phone]

Ⅰ . Consolidated Financial Results

1. Trends in consolidated profit

	The "★" symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.			Unit: Billions of yen	FY2021-2025
		FY 2022 results				FY 2023 results			FY 2023 forecasts
									Change	Rate of			Medium Term
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep		Jan - Dec	Progress	Business Plan
		amount	change	Financial KPIs
Revenue	87.8	185.3	283.8	398.4	93.5	199.2	306.1		22.3	8%	426.0	72%
★ CAGR (compared to FY 2020)	-	-	-	11.9%	-	-	-		-	-	10.2%	-	10% or higher
Cost of sales	(22.2)	(43.4)	(64.1)	(86.9)	(18.9)	(47.0)	(77.0)		(12.8)	20%	(100.0)	77%
Gross profit	65.6	141.9	219.6	311.5	74.6	152.2	229.1		9.4	4%	326.0	70%
Gross profit to revenue ratio	74.7%	76.6%	77.4%	78.2%	79.7%	76.4%	74.8%		-	-	76.5%	-
Selling, general and administrative	(36.1)	(76.4)	(117.3)	(166.2)	(41.8)	(82.4)	(119.3)		(2.0)	2%	(162.0)	74%
expenses
Research and development expenses	(13.6)	(27.9)	(44.1)	(62.9)	(16.6)	(33.7)	(51.2)		(7.0)	16%	(79.0)	65%
★ R&D expense ratio	15.5%	15.1%	15.6%	15.8%	17.8%	16.9%	16.7%		-	-	18.5%	-	Target of 18-20%
Share of profit (loss) of investments	1.4	2.4	2.6	4.3	0.8	1.4	2.3		(0.4)	(14)%	3.0	76%
accounted for using equity method
Core operating profit	17.3	39.9	60.9	86.7	17.0	37.5	60.9		0.0	0%	88.0	69%
★ Core operating profit ratio	19.8%	21.5%	21.4%	21.8%	18.2%	18.8%	19.9%		-	-	20.7%	-	25% or higher
Other income	0.4	0.6	1.0	1.7	0.2	0.5	16.6		15.6	-
Other expenses	(0.2)	(1.2)	(5.1)	(23.1)	(2.6)	(14.2)	(16.6)		(11.6)	228%
Finance income (costs)	1.2	4.2	3.6	2.2	1.0	2.2	3.5		(0.0)	(2)%
Profit before tax	18.7	43.5	60.4	67.6	15.6	26.0	64.3		3.9	7%	86.0	75%
Income tax expense	(2.7)	(8.5)	(11.2)	(14.0)	(2.8)	(4.4)	(10.8)		0.4	(4)%	(16.0)	67%
Ratio of income tax burden	14.3%	19.5%	18.5%	20.7%	18.1%	16.9%	16.8%		-	-	18.6%	-
Profit	16.0	35.0	49.2	53.6	12.8	21.6	53.6		4.3	9%	70.0	77%
Profit to revenue ratio	18.3%	18.9%	17.3%	13.4%	13.6%	10.9%	17.5%		-	-	16.4%	-
EPS (¥/share)	29.85	65.16	91.57	99.68	23.74	40.27	99.62		8.05	-	130.23	-
Core EPS (¥/share)*1	29.52	66.14	97.70	131.19	27.33	61.40	99.69		1.99	-	136.37	-
Annual dividend (¥/share)				51.00							54.00	-
★ Dividend payout ratio (%)*2				38.9							39.6	-	Target of 40%
★ROE (%)				7.1							8.9	-	10% or higher

*1 Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting "other income," "other expenses" and the related "income tax expense" from "profit") by the average number of shares during the period.

*2 Dividend payout ratio is shown based on core EPS.

								Unit: Billions of yen
		FY 2022 results				FY 2023 results
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change	Rate of
	amount	change
Revenue	87.8	97.5	98.5	114.6	93.5	105.7	106.8	8.3	8%
Cost of sales	(22.2)	(21.2)	(20.8)	(22.8)	(18.9)	(28.1)	(29.9)	(9.2)	44%
Gross profit	65.6	76.3	77.7	91.8	74.6	77.6	76.9	(0.8)	(1)%
Gross profit to revenue ratio	74.7%	78.2%	78.9%	80.1%	79.7%	73.4%	72.0%	-	-
Selling, general and administrative	(36.1)	(40.4)	(40.8)	(48.9)	(41.8)	(40.6)	(36.9)	3.9	(10)%
expenses
Research and development expenses	(13.6)	(14.3)	(16.2)	(18.8)	(16.6)	(17.0)	(17.5)	(1.3)	8%
★ R&D expense ratio	15.5%	14.7%	16.5%	16.4%	17.8%	16.1%	16.4%	-	-
Share of profit (loss) of investments	1.4	0.9	0.3	1.7	0.8	0.6	0.9	0.6	233%
accounted for using equity method
Core operating profit	17.3	22.6	21.0	25.8	17.0	20.5	23.4	2.5	12%
★ Core operating profit ratio	19.8%	23.1%	21.3%	22.5%	18.2%	19.4%	21.9%	-	-
Other income	0.4	0.2	0.5	0.7	0.2	0.3	16.1	15.6	-
Other expenses	(0.2)	(1.0)	(3.9)	(18.0)	(2.6)	(11.6)	(2.5)	1.4	(36)%
Finance income (costs)	1.2	3.1	(0.6)	(1.4)	1.0	1.3	1.3	1.9	-
Profit before tax	18.7	24.8	16.9	7.2	15.6	10.5	38.3	21.4	126%
Income tax expense	(2.7)	(5.8)	(2.7)	(2.8)	(2.8)	(1.6)	(6.4)	(3.7)	134%
Profit	16.0	19.0	14.2	4.4	12.8	8.9	31.9	17.7	125%
Profit to revenue ratio	18.3%	19.5%	14.4%	3.8%	13.6%	8.4%	29.9%	-	-

- 1 -

2. Revenue by regional control function									Unit: Billions of yen
		FY 2022 results			FY 2023 results		FY 2023 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change	Jan - Dec	Progress
	amount
Japan	35.4	72.8	109.2	148.7	34.0	70.9	107.0	(2.3)	145.6	73%
North America	20.7	47.5	75.9	112.6	25.7	60.3	92.9	17.0	132.5	70%
EMEA	14.5	30.9	48.0	66.9	15.4	30.8	45.7	(2.3)	66.1	69%
APAC	7.2	14.8	22.5	30.1	7.4	16.0	26.0	3.5	34.5	75%
Others	9.8	19.3	28.1	40.1	11.0	21.2	34.5	6.3	47.4	73%
Total consolidated revenue	87.8	185.3	283.8	398.4	93.5	199.2	306.1	22.3	426.0	72%

• Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization based on four regions of Japan, North America, EMEA and APAC, a functional organization, and a product organization (product franchises).
• EMEA consists of Europe, the Middle East, Africa, etc.
• Others consists of revenue from technology out-licensing, original equipment manufacturing, etc.

3. Revenue by location of customer										Unit: Billions of yen
			FY 2022 results			FY 2023 results		FY 2023 forecasts
		Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Percentage of	Jan - Mar	Jan - Jun	Jan - Sep	Percentage of	Jan - Dec	Percentage of
		consolidated	consolidated	consolidated
						revenue				revenue		revenue
Japan	36.9	75.8	111.3	154.6	39%	35.0	73.7	111.1	36%	153.3	36%
International	50.9	109.5	172.5	243.7	61%	58.5	125.6	194.9	64%	272.7	64%
	Americas	28.2	62.2	99.8	143.9	36%	34.2	76.9	121.5	40%	169.2	40%
	Of which, the U.S.	27.3	60.3	97.1	139.9	35%	32.8	74.4	117.7	38%	162.6	38%
	Europe	13.5	28.8	44.9	62.3	16%	14.4	28.5	40.9	13%	61.9	15%
	Asia	9.1	18.4	27.6	37.4	9%	9.7	19.8	31.9	10%	40.9	10%
	Others	0.0	0.1	0.2	0.2	0%	0.2	0.4	0.7	0%	0.7	0%
Total consolidated revenue	87.8	185.3	283.8	398.4	100%	93.5	199.2	306.1	100%	426.0	100%

* Revenue by location of customer is classified by region or country based on location of customer.

4. Capital expenditures and intangible assets investment, depreciation and amortization				Unit: Billions of yen
		FY 2022 results			FY 2023 results		FY 2023
					forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
Capital expenditures (property, plant and equipment)*	1.8	5.0	10.3	17.7	3.7	7.0	10.5	24.0
Intangible assets investment	1.0	3.1	4.9	13.3	2.3	4.7	13.6	15.0
Total	2.8	8.2	15.2	31.0	6.0	11.7	24.1	39.0
Depreciation (property, plant and equipment)	2.9	6.0	9.0	11.4	3.1	6.3	9.7	13.0
Amortization (intangible assets)	1.7	3.5	5.3	7.0	1.8	3.6	5.8	7.0
Total	4.6	9.5	14.3	18.5	4.8	9.9	15.5	20.0

• Acquisitions of right-of-use assets are not included.

5. Number of employees by regional control function

		FY 2022 results			FY 2023 results
	As of March 31	As of June 30	As of September	As of December	As of March 31	As of June 30	As of September	Change
			30	31			30	amount
Japan	4,035	4,114	4,146	4,135	4,154	4,236	4,207	61
North America	446	490	532	560	574	608	630	98
EMEA	781	768	747	729	743	714	587	(160)
APAC	536	540	555	558	571	578	568	13
Total	5,798	5,912	5,980	5,982	6,042	6,136	5,991	11

Ⅱ. Consolidated Statement of Cash Flows

Unit: Billions of yen

		FY 2022 results			FY 2023 results
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change
	amount
Cash flows from operating activities	8.8	22.5	35.5	48.7	29.4	60.3	84.3	48.7
Cash flows from investing activities	(4.6)	(6.8)	(13.4)	(17.2)	(9.1)	(14.0)	(12.5)	0.9
Cash flows from financing activities	(13.2)	(14.1)	(27.9)	(29.0)	(15.2)	(16.1)	(31.4)	(3.5)
Effect of exchange rate changes on cash and cash equivalents	0.4	3.3	3.5	1.7	0.5	2.6	2.7	(0.8)
Net increase (decrease) in cash and cash equivalents	(8.6)	4.8	(2.3)	4.1	5.7	32.9	43.1	45.4
Cash and cash equivalents at beginning of period	335.1	335.1	335.1	335.1	339.2	339.2	339.2	4.1
Cash and cash equivalents at end of period	326.5	339.9	332.8	339.2	344.8	372.1	382.3	49.5

- 2 -

Ⅲ. Revenue from Main Products

								Unit: Billions of yen
			FY 2022 results			FY 2023 results		FY 2023
						forecasts
	Product name
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Change	Jan - Dec	Progress
									amount
	Nesp	0.8	1.6	2.5	3.4	0.8	1.5	2.3	(0.2)	2.8	82%
	Darbepoetin Alfa Injection Syringe [KKF]	4.4	8.8	13.2	17.6	3.5	6.9	10.3	(2.9)	13.8	75%
	Duvroq	1.1	2.7	4.4	6.6	1.8	4.2	6.9	2.4	7.8	88%
	Regpara	0.5	1.1	1.7	2.2	0.4	0.8	1.2	(0.4)	2.1	60%
	Orkedia	2.2	4.9	7.5	10.3	2.2	5.0	7.6	0.1	11.2	68%
	Rocaltrol	0.7	1.5	2.3	3.1	0.7	1.4	2.1	(0.2)	2.4	86%
	Onglyza	1.2	2.6	3.8	5.2	1.1	2.2	3.2	(0.6)	4.3	74%
	Coniel	0.6	1.1	1.6	2.0	0.4	0.7	1.1	(0.5)	1.4	76%
	G-Lasta	7.1	14.8	22.7	31.1	7.0	15.0	23.2	0.5	33.5	69%
Japan	Fentos	0.8	1.8	2.7	3.7	0.7	1.6	2.5	(0.2)	3.3	76%
Poteligeo	0.5	1.0	1.5	2.0	0.4	0.9	1.4	(0.0)	2.0	73%
	Rituximab BS [KHK]	2.5	5.0	7.6	10.3	2.2	4.4	6.7	(0.9)	8.7	77%
	Romiplate	2.2	4.8	7.5	10.4	2.7	5.7	8.7	1.2	11.2	77%
	Allelock	2.4	3.8	4.8	6.0	1.9	3.1	4.1	(0.6)	4.7	88%
	Patanol	1.8	2.2	2.4	2.8	1.4	1.5	1.7	(0.7)	1.9	90%
	Dovobet	1.7	3.8	5.6	7.8	1.8	3.9	5.7	0.1	7.6	75%
	Lumicef	0.7	1.5	2.2	3.0	0.6	1.3	2.1	(0.1)	3.5	59%
	Nouriast	1.8	3.9	5.9	8.0	1.7	3.7	5.5	(0.3)	7.5	73%
	HARUROPI	0.8	1.8	2.8	4.0	0.9	2.1	3.2	0.4	4.7	68%
	Depakene	0.8	1.7	2.5	3.3	0.6	1.4	2.1	(0.4)	3.0	69%
	Crysvita	2.0	4.1	6.4	8.9	2.3	4.8	7.4	1.0	11.1	67%
	Crysvita	22.2	49.4	78.7	118.2	27.1	61.9	95.7	17.0	138.0	69%
	Poteligeo	4.2	10.3	16.1	22.3	5.8	12.5	19.9	3.8	27.5	72%
	Nourianz	1.1	2.6	4.5	6.5	1.7	3.5	5.5	1.0	7.5	73%
International	Abstral	1.4	3.6	5.4	6.9	1.1	2.6	2.9	(2.4)	2.0	149%
Pecfent	1.0	1.7	3.0	3.7	0.9	1.7	2.1	(0.9)	1.2	169%
	Moventig	0.7	1.5	2.2	3.1	0.8	1.6	1.9	(0.4)	1.2	155%
	Adcal-D3	0.7	1.5	2.2	3.0	0.7	1.5	1.7	(0.5)	1.2	134%
	Nesp	1.9	3.9	5.9	7.6	2.2	4.4	7.0	1.2	8.0	89%
	Regpara	1.0	2.0	2.9	3.9	0.9	1.9	3.1	0.1	3.9	79%
	Neulasta/Peglasta	1.7	3.0	4.4	5.6	1.3	2.8	4.5	0.1	5.7	79%
	Gran	2.1	3.8	6.4	8.2	1.4	3.2	5.2	(1.2)	8.2	63%
Technology out-licensing	7.8	15.7	23.8	33.8	9.2	18.4	30.1	6.3	40.2	75%
	Of which, Benralizumab royalty	4.7	9.3	15.4	21.6	5.7	11.6	19.1	3.8

• Revenue from products is classified into Japan or international (other than Japan) based on consolidated revenue of regional control functions.
• Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.
• The revenue for Abstral, Pecfent, Moventig and Adcal-D3 does not include the royalties revenue from the joint venture with Grünenthal in August 2023 and thereafter.
• Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

- 3 -

Ⅲ. Revenue from Main Products

Product name

	Nesp
	Darbepoetin Alfa Injection Syringe [KKF]
	Duvroq
	Regpara
	Orkedia
	Rocaltrol
	Onglyza
	Coniel
	G-Lasta
Japan	Fentos
Poteligeo
	Rituximab BS [KHK]
	Romiplate
	Allelock
	Patanol
	Dovobet
	Lumicef
	Nouriast
	HARUROPI
	Depakene
	Crysvita

Unit: Billions of yen

	FY 2022 results			FY 2023 results
Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change
amount
0.8	0.8	0.9	0.9	0.8	0.8	0.8	(0.1)
4.4	4.4	4.4	4.4	3.5	3.4	3.5	(0.9)
1.1	1.6	1.8	2.1	1.8	2.4	2.6	0.9
0.5	0.6	0.5	0.5	0.4	0.5	0.4	(0.1)
2.2	2.7	2.6	2.8	2.2	2.7	2.6	(0.0)
0.7	0.8	0.8	0.8	0.7	0.7	0.7	(0.1)
1.2	1.3	1.3	1.3	1.1	1.1	1.0	(0.2)
0.6	0.5	0.4	0.4	0.4	0.4	0.4	(0.1)
7.1	7.7	7.9	8.4	7.0	7.9	8.2	0.4
0.8	1.0	0.9	1.0	0.7	0.9	0.9	(0.1)
0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.0
2.5	2.5	2.5	2.7	2.2	2.3	2.2	(0.3)
2.2	2.6	2.7	2.9	2.7	3.0	3.0	0.2
2.4	1.4	0.9	1.2	1.9	1.2	1.0	0.1
1.8	0.3	0.3	0.4	1.4	0.2	0.2	(0.1)
1.7	2.1	1.8	2.1	1.8	2.1	1.8	(0.0)
0.7	0.8	0.7	0.8	0.6	0.7	0.7	(0.0)
1.8	2.1	2.0	2.1	1.7	2.0	1.9	(0.1)
0.8	1.0	1.0	1.2	0.9	1.1	1.1	0.1
0.8	0.8	0.8	0.8	0.6	0.7	0.7	(0.1)
2.0	2.2	2.3	2.5	2.3	2.5	2.6	0.3

	Crysvita	22.2	27.2	29.3	39.5	27.1	34.8	33.8	4.5
	Poteligeo	4.2	6.1	5.8	6.2	5.8	6.6	7.5	1.7
	Nourianz	1.1	1.4	1.9	2.0	1.7	1.9	2.0	0.1
International	Abstral	1.4	2.2	1.8	1.5	1.1	1.4	0.4	(1.4)
Pecfent	1.0	0.7	1.3	0.7	0.9	0.9	0.4	(1.0)
	Moventig	0.7	0.8	0.8	0.8	0.8	0.8	0.3	(0.5)
	Adcal-D3	0.7	0.8	0.7	0.8	0.7	0.8	0.2	(0.5)
	Nesp	1.9	2.0	2.0	1.7	2.2	2.2	2.6	0.7
	Regpara	1.0	1.0	0.9	1.0	0.9	1.0	1.2	0.2
	Neulasta/Peglasta	1.7	1.3	1.4	1.3	1.3	1.5	1.7	0.3
	Gran	2.1	1.8	2.5	1.8	1.4	1.8	2.0	(0.6)
Technology out-licensing	7.8	7.9	8.1	10.0	9.2	9.2	11.8	3.6
	Of which, Benralizumab royalty	4.7	4.6	6.1	6.2	5.7	5.9	7.5	1.4

• Revenue from products is classified into Japan or international (other than Japan) based on consolidated revenue of regional control functions.
• Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.
• The revenue for Abstral, Pecfent, Moventig and Adcal-D3 does not include the royalties revenue from the joint venture with Grünenthal in August 2023 and thereafter.
• Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

- 4 -

Ⅲ. Revenue from Main Products

Revenue of three global strategic products

			Unit: Billions of yen
	FY 2022 results	FY 2023 results		FY 2023 forecasts
Product name
Jan - Mar Jan - Jun Jan - Sep Jan - Dec	Jan - Mar Jan - Jun Jan - Sep	Change	Jan - Dec Progress
	amount

	Crysvita	24.2	53.5	85.1	127.1	29.4	66.7	103.1	18.0	149.1	69%
		Japan	2.0	4.1	6.4	8.9	2.3	4.8	7.4	1.0	11.1	67%
		North America	15.8	35.9	57.4	87.0	18.8	46.0	70.2	12.8
		[Millions of USD]	139	298	456	662	143	344	530	74
		EMEA	6.3	13.5	21.2	31.0	8.0	15.3	24.5	3.2	138.0	69%
		[Millions of GBP]	41	85	133	192	50	93	151	18
		APAC	0.0	0.1	0.1	0.3	0.3	0.6	1.1	0.9
	Poteligeo	4.7	11.3	17.5	24.2	6.3	13.4	21.3	3.8	29.5	72%
		Japan	0.5	1.0	1.5	2.0	0.4	0.9	1.4	(0.0)	2.0	73%
		North America	3.3	8.1	12.6	17.2	4.3	9.4	15.1	2.5	19.4	78%
		[Millions of USD]	29	67	100	132	33	70	114	14	149
		EMEA	0.9	2.1	3.5	5.1	1.5	3.1	4.8	1.3	8.0	61%
		[Millions of GBP]	6	14	22	32	9	19	30	8	50
		APAC	-	-	-	-	-	-	0.0	0.0	-	-
	Nouriast/Nourianz	2.9	6.5	10.3	14.5	3.3	7.2	11.0	0.7	15.1	73%
		Japan	1.8	3.9	5.9	8.0	1.7	3.7	5.5	(0.3)	7.5	73%
		North America	1.1	2.6	4.5	6.5	1.7	3.5	5.5	1.0	7.5	73%
		Total of three global	31.8	71.3	113.0	165.8	39.0	87.3	135.5	22.5	193.6	70%
		strategic products
								Unit: Billions of yen
		Product name		FY 2022 results			FY 2023 results
		Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Change
			amount
	Crysvita	24.2	29.4	31.6	42.0	29.4	37.3	36.4	4.8
		Japan	2.0	2.2	2.3	2.5	2.3	2.5	2.6	0.3
		North America	15.8	20.0	21.5	29.6	18.8	27.2	24.1	2.6
		[Millions of USD]	139	159	158	206	143	202	186	28
		EMEA	6.3	7.1	7.8	9.7	8.0	7.3	9.2	1.4
		[Millions of GBP]	41	44	47	59	50	43	57	10
		APAC	0.0	0.0	0.1	0.2	0.3	0.3	0.5	0.4
	Poteligeo	4.7	6.6	6.3	6.7	6.3	7.1	8.0	1.7
		Japan	0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.0
		North America	3.3	4.8	4.4	4.6	4.3	5.1	5.7	1.3
		[Millions of USD]	29	38	33	32	33	37	44	11
		EMEA	0.9	1.2	1.4	1.6	1.5	1.6	1.8	0.4
		[Millions of GBP]	6	8	8	10	9	9	11	3
		APAC	-	-	-	-	-	-	0.0	0.0
	Nouriast/Nourianz	2.9	3.6	3.9	4.1	3.3	3.9	3.8	(0.0)
		Japan	1.8	2.1	2.0	2.1	1.7	2.0	1.9	(0.1)
		North America	1.1	1.4	1.9	2.0	1.7	1.9	2.0	0.1
		Total of three global	31.8	39.5	41.7	52.8	39.0	48.3	48.2	6.5
		strategic products

• Revenue is classified based on consolidated revenue from regional control functions.
• The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.

- 5 -

Ⅳ．R&D Pipeline

antibody

Nephrology

protein

small molecule

◎ New Molecular Entity

Updated since Dec. 31, 2022

Updated since Jun. 30, 2023

As of Sep 30, 2023

Code Name

Generic Name

Formulation

KHK7580

Evocalcet

Oral

KW-3357

Antithrombin Gamma

Injection

KHK7791

Tenapanor Hydrochloride

Oral

KRN1493

Cinacalcet Hydrochloride

Oral

Oncology

Code Name

Generic Name

Formulation

KW-0761

Mogamulizumab

Injection

KRN125

Pegfilgrastim

Injection

				Stage
Mechanism of Action	Indication	Area				Approve
		PhⅠ	PhⅡ	PhⅢ	Filed
		d
		CN
Calcimimetic	Secondary Hyperparathyroidism	KR
		TW
Recombinant Human	Preeclampsia	JP
Antithrombin
NHE3 Inhibitor	Hyperphosphatemia in Patients	JP
on Dialysis
Calcimimetic	Primary Hyperparathyroidism	HK

				Stage
Mechanism of Action	Indication	Area				Approve
		PhⅠ	PhⅡ	PhⅢ	Filed
		d
		KW
		IL
Anti-CCR4 Humanized	Mycosis Fungoides and
Antibody	Sézary Syndrome
		ME
		RS
Long-Acting	Mobilization of Hematopoietic
Stem Cells into Peripheral Blood
Granulocyte Colony-	JP
Stimulating Factor	for Autologous Blood Stem Cell
Transplantation

[In-House or Licensed]

Remarks

[Mitsubishi Tanabe Pharma] product name in Japan: Orkedia

[In-House]

product name in Japan: Acoalan

[Ardelyx]

[NPS Pharmaceuticals]

product name in Japan: Regpara

[In-House or Licensed]

Remarks

[In-House]

POTELLIGENT

product name in Japan, US and Europe: Poteligeo

[Amgen K-A]

product name in Japan: G-Lasta

-6-

Ⅳ．R&D Pipeline

antibody

protein

small molecule

◎ New Molecular Entity

Updated since Dec. 31, 2022

Immunology/Allergy

Updated since Jun. 30, 2023

Code Name					Stage
Generic Name	Mechanism of Action	Indication	Area				Approve
Formulation			PhⅠ	PhⅡ	PhⅢ	Filed
		d
		Ankylosing Spondylitis	TH
KHK4827	Anti-IL-17 Receptor A	Non-radiographic Axial	TH
Brodalumab	Spondyloarthritis
Fully Human Antibody
Injection
		Palmoplantar Pustulosis	JP
		Systemic Sclerosis	JP
			JP
			NA
◎KHK4083/AMG 451			Europe
Anti-OX40 Fully Human		Middle East
Rocatinlimab	Atopic Dermatitis
Antibody	CN
Injection
		Asia
			Oceania
			others
◎KK4277		Autoimmune Disease	JP
Injection		Asia

[In-House or Licensed]

Remarks

[Amgen K-A]

product name in Japan and Asia: Lumicef

[In-House]

POTELLIGENT

Fully human antibody production technology

Collaboration agreement with Amgen for the development of KHK4083/AMG 451 in all the countries except for Japan.

[SBI Biotech]

Other

Code Name					Stage			[In-House or Licensed]
Generic Name	Mechanism of Action	Indication	Area
			Approve	Remarks
Formulation			PhⅠ	PhⅡ	PhⅢ	Filed
		d
			OM
			QA
			UAE

		Tumor Induced Osteomalacia	KW
		BH
		(TIO)
			RS
KRN23	Anti-FGF23 Fully		ME
Burosumab
Human Antibody
Injection		MK
			MO
		X-linked Hypophosphatemia	MK
		(XLH)
			RS
			ME

[In-House]

Fully human antibody production technology

Jointly Developed with Ultragenyx in US and Europe product name in Japan, US and Europe: Crysvita

AMG531	Thrombopoietin Receptor	Aplastic Anemia Previously	JP		[Amgen K-A]
Romiplostim	Agonist	Untreated with		PhⅡ/	product name in Japan:
Injection	Immunosuppressive Therapy	Asia	Romiplate
	PhⅢ
KW-3357	Recombinant Human	Disseminated Intravascular			[In-House]
Antithrombin Gamma	Coagulation, Congenital	Europe
Antithrombin		product name in Japan: Acoalan
Injection	Antithrombin Deficiency
KHK4951	VEGF Receptor Tyrosine	Neovascular (wet) Age-Related
Tivozanib	JP		[In-House]
Kinase Inhibitor	Macular Degeneration
Ophthalmic

Note: Our main progress from September 30, 2023 is as follows.

We decided to discontinue the development of KW-3357 (product name in Japan: Acoalan) for treatment for preeclampsia in the nephrology field.

-7-